

Pinnacle Clinical Research, a Portfolio Company of LongueVue Capital, Acquired The Cognitive and Research Center of New Jersey

PINNACLE
CLINICAL RESEARCH

Acquired



CRCNJ
The Cognitive and Research Center
of New Jersey, LLC

134th

Pharma
Services Deal

20th

Clinical Site
Transaction

94th

Clinical Trials
Deal

Pinnacle Clinical Research, a Portfolio Company of LongueVue Capital, Acquired The Cognitive and Research Center of New Jersey to Expand Clinical Trial Site Network to Expand its CNS Trial Execution Capabilities

Executing complex protocols while demonstrating high quality in clinical trials poses an ongoing hurdle. Especially in Alzheimer's Disease (AD) trials, the complex nature of these protocols creates high barriers to entry for new sites trying to enter the space and deters many sites from participating in AD trials.

The Cognitive and Research Center of New Jersey ("CRCNJ") is a Springfield-based research center dedicated to providing resources for those affected by Alzheimer's Disease and other Central Nervous System (CNS) diseases. CRCNJ's reputation and exclusive focus on CNS diseases positioned it as the perfect ally for Pinnacle Clinical Research ("Pinnacle"). The strategic partnership furthers Pinnacle's ongoing

expansion into CNS, particularly AD, given CRCNJ's experience and reputation within the AD space. This collaboration will enhance Pinnacle's capacity to recruit suitable patients for trials and expand its network of research sites to include twelve sites across the US.

Crosstree utilized its wealth of experience in clinical research sites to assist Pinnacle in assessing potential partners. Crosstree aligned current market trends with Pinnacle's capabilities to construct a compelling narrative to present to potential partners, and ultimately identified CRCNJ as an organization that aligns with their growth objectives.

"Crosstree's proven track record of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today."



JASON LAYTON
Managing Director

jason.layton@crosstreecapital.com

813-578-7109

Crosstree's experts are specialists in the nuances of the health sciences, prioritizing corporate core values and providing:

Deep analytics of capabilities and gaps

Systemized tactical strategies and a road map to success

Engaged experts in market analysis, financials, and premium valuations

Targeted and qualified prospects

Up-to-date industry trend analysis and forecasting

Meeting the needs of both the buyer and the seller by the numbers and beyond is Crosstree's specialty.



About Pinnacle Clinical Research

Pinnacle Clinical Research, founded by Dr. Stephen Harrison, specializes in complex therapeutic areas, offering high-quality patient care and superior enrollment timelines across twelve stand-alone sites. Led by a renowned physician team, Pinnacle focuses on pioneering treatments for complex diseases and addressing the needs of populations that have been historically underrepresented in clinical trials. The organization provides sponsors with a scaled network that ensures deep therapeutic expertise and superior clinical execution.

Pinnacle Clinical Research is a portfolio company of LongueVue Capital.

About The Cognitive and Research Center of New Jersey

Headquartered in Springfield, New Jersey, CRCNJ is a leading Northeast-based CNS clinical research site with a focus on AD. CRCNJ operates one site in Springfield, New Jersey and is currently opening its second site location in Ridgewood, New Jersey. Dr. Michelle Papka, a respected thought leader in AD who holds deep relationships with top AD sponsors, founded CRCNJ in 2009 to establish a stronghold for CNS clinical trials in the New Jersey market. CRCNJ's reputation for top quality care is a core driver of patient referrals in the traditionally difficult-to-recruit CNS space.



Other Recent Pharma Services Transactions:

